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Site speciﬁc targeting remains elusive for gene and stem cell therapies in the cardiovascular ﬁeld. One
promising option involves use of devices that deliver larger and more sustained cell/gene payloads to
speciﬁc disease sites using the versatility of percutaneous vascular access technology. Smooth muscle
cells (SMCs) engineered to deliver high local concentrations of an angiogenic molecule (VEGF) were
placed in an intravascular cell delivery device (ICDD) in a porcine model of chronic total occlusion (CTO)
involving ameroid placement on the proximal left circumﬂex (LCx) artery. Implanted SMC were retained
within the ICDD and were competent for VEGF production in vitro and in vivo. Following implantation,
micro-CT analyses revealed that ICDD-VEGF signiﬁcantly enhanced vasa vasora microvessel density with
a concomitant increase in tissue VEGF protein levels and formation of endothelial cell colonies sug-
gesting increased angiogenic potential. ICDD-VEGF markedly enhanced regional blood ﬂow determined
by microsphere and contrast CT analysis translating to a functional improvement in regional wall motion
and global left ventricular (LV) systolic and diastolic function. Our data indicate robust, clinically relevant
angiogenesis can be achieved in a human scale porcine chronic vascular occlusion model following ICDD-
VEGF-based delivery of angiogenic cells. This may have implications for percutaneous delivery of
numerous therapeutic factors promoting creation of microvascular bypass networks in chronic vaso-
occlusive diseases.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Chronic vaso-occlusive disease remains the Achilles heel of
cardiovascular medicine and surgery [1]. Percutaneous revascu-
larization of chronic occlusion is hampered by the risk of arterials Institute, University College
r Ltd. This is an open access articleperforation, reduced primary success and high restenosis rates
[2]. Moreover, conventional surgical strategies aimed at bypass-
ing these occlusive lesions are frequently not feasible because of
the poor condition of distal blood vessels [3] or co-morbidities in
the target population [4]. The need for alternative revasculari-
zation strategies is great and for more than two decades, gene
and cell therapy have offered tantalizing prospects for alleviation
of such no-option occlusive vasculopathies. However, despite
initial promise, signiﬁcant barriers have emerged to both vector
delivery and exogenous cell retention at the site of vascular
disease [5].under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
A.H.S. Kumar et al. / Biomaterials 35 (2014) 9012e9022 9013Previous animal studies employing local VEGF-based gene
therapy strategies have been limited by the amount and duration
of gene delivery that can be achieved in the vessel wall [6] as
well as safety concerns including angioma formation [7]. To
achieve sustained delivery at a safe local dose, we adopted a
strategy of placing therapeutic cells, engineered with an angio-
genic gene, into a percutaneously deliverable intravascular cell
delivery device (ICDD) incorporating a non-woven matrix that
allowed a 3D cell mass to be stably conditioned in culture (Fig. 1).
The approach of utilizing an expanded autologous cell source as
an angiogenic gene/protein delivery platform is considered to
obviate some of the reliability, dosing and technical challenges
associated with direct in vivo viral vector administration [8]. WeFig. 1. Overview of ICDD strategy and chronic total occlusion (CTO) study protocol. A
accomodate adherent Dil-labeled SMC. B. CTO was induced by ameroid constrictor placem
transduced with a retroviral VEGF expression vector and loaded onto an ICDD prior to deplo
analyses were performed at the time of ICDD-VEGF placement and one month later (sacriﬁhypothesized that such an ICDD would elicit a more robust,
stable and reliable local biologic response than cells or genes
alone and that this would facilitate targeted, sustained and
therapeutic angiogenesis in the myocardium supplied by the
occlusive artery.
We selected autologous SMCs as a conduit for VEGF delivery and
expression for several reasons: 1) we hypothesized that these cells
would be amore stable source for gene transfer than vector alone 2)
in previous experiments, we had shown that SMC could be deliv-
ered on a stent-based platform in 100-fold greater numbers than
endothelial cells [9]. 3) SMC grow in multilayers within the mesh
allowing development of a stable organoid that does not embolize
4) autologous SMC are also a clinically translatable cell as they can. SMC within ICDD Inset showing non-woven mesh topography with the ability to
ent on the proximal LCx. SMCs simultaneously harvested from the jugular vein were
yment four weeks after ameroid placement. CT, microsphere and conductance catheter
ce) along with further tissue analyses.
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ripheral blood progenitors in substantial numbers and 5) SMC
secrete complementary growth factors such as PDGF in addition to
VEGF165 which might encourage local arteriogenesis rather than
capillary-like angiogenesis seen with previous single VEGF gene
therapy [10]. Previously, cell viability and local stability of GFP re-
porter-labeled SMC at 30 days in the normal artery was established
using this platform [9]. We thus engineered an ICDD to provide
stable SMC-based VEGF delivery in vivo. In the current study,
therapeutic efﬁcacy of this cell/gene delivery system was struc-
turally and functionally assessed in terms of improvement in
myocardial blood ﬂow (MBF) and global left ventricular function in
a porcine model of chronic ischemia. Additionally, ischemic zone
arteriogenesis and circulating progenitor cell responses were
investigated. Development of this ICDD platform may have impli-
cations for gene and cell therapy treatment of numerous cardio-
vascular disease processes including cardiac and peripheral
ischemia.2. Materials & methods
2.1. ICDD preparation, smooth muscle cell harvest, transduction and seeding
Our delivery strategy involved genetically engineered and non-transduced
control SMC seeded in a non-woven metallic matrix ﬁxed on a conventional
stent (Fig. 1(A)) and was prepared as previously described [9]. Brieﬂy, a
5 mm  20 mm mesh was made from a ﬁber matrix produced by compressing
metallic ﬁbers (Bekaert Fibre Technologies, Marietta, GA) into a felt and then
sintering the matrix. This was attached to a fully expanded 20 mm stent and
sealed with a gas tungsten arc welding torch. The ICDD was cleaned by sonication
several times in absolute ethyl alcohol, washing in Haemo-Sol (4.5 g/250 ml of
water) for 30 min of rocking, rinsing several times in ﬁltered sterile water,
washing in absolute alcohol, and gas sterilized. The ICDD was coated with 10 mg/
ml ﬁbronectin (Sigma) prior to cell seeding. Animals were subsequently ran-
domized to receive either Control or VEGF-secreting ICDD. Autologous porcine
smooth muscle cells were obtained from a 2e3 cm segment of external jugular
vein obtained at the initial surgical encounter. Cells were dispersed from the in-
tima and media of the vessel through a series of collagenase and elastase di-
gestions [11]. SMCs at culture passage 1e2 were transduced with retroviral VEGF
vector at 100 MOI, followed by puromycin (10 mg/ml, Sigma) selection. Medium
was changed to M199 (serum free, Sigma), and conditioned medium was collected
after 24 h replacement. ELISA (Abcam) and immunoﬂouresence (rabbit anti-
human VEGF, Santa Cruz) was used to conﬁrm VEGF production. Conﬁrmation
of smooth muscle cell identity was made through positive a-smooth muscle actin,
calponin and smooth muscle myosin heavy chain and lack of von Willebrand
factor staining, control or VEGF-secreting were seeded on the mesh backbone of
the ICDD at a density of 1.0  107 cells/cm2. ICDD-Control devices were seeded at
the same density with non-engineered SMC.2.2. Chronic total vascular occlusion porcine model
All animal protocols were approved by the Institutional Animal Use and Care
Committee at the Mayo Clinic, Rochester, USA and University College Cork, Cork,
Ireland and were in accord with the National Institutes of Health guide for the
care and use of laboratory animals. Thirty seven domestic female Yorkshire/
Landrace pigs (22e27 kg) were used in this study (10 for ICDD implantation
without CTO, 11 for regional blood ﬂow (RBF) analysis with CTO, 16 for functional
studies with CTO, four deaths overall). Pigs were initially anesthetized with
xylazine (1.6 mg/kg), telazol (3.3 mg/kg) and glycopyrolate (0.14 mg/kg) in a
weight adjusted manner maintained using inhalational isoﬂuorane 1.5%. Using
sterile technique, a 2.5 mm ameroid constrictor was placed via a left thoracotomy
on the left circumﬂex artery allowing sufﬁcient space for later stent deployment
[12]. During this procedure the external jugular vein was also obtained for smooth
muscle cell harvest. After recovery the animals remained in colony housing for 4
weeks. Surgical wounds were closed using 6/0 suture and sealed with Aluspray
aerosol bandage (Neogen). Gentamycin: 4 mg/kg s.c. was administered as a single
dose during the course of the ameroid placement procedure and Piperacillin-
Tazobactum (4 g/0.5 g respectively) was additionally administered daily for ﬁrst
ﬁve days post-procedure. Analgesia was delivered as s.c. administration of car-
profen (2 mg/kg) every 24 h for three days following the procedures. Following
the initial phase of procedure optimization, a mortality rate of ~10% which
occurred in the early peri- and post-operative phases was observed. All animals
that died were excluded from analysis. There was no difference in mortality be-
tween treatment groups.2.3. ICDD deployment and coronary angiography
At 4 weeks following ameroid placement, occlusion was veriﬁed by coronary
angiography and collateral formation was assessed (Fig. 1(B)) and animals with
collaterals were excluded from further study. Immediately following diagnostic
angiography balloon size was selected based on angiographic appearance
(2.5e3.5 mm) and the ICDD crimped using a mechanical crimping device and then
balloon mounted. Deployment was performed using a 8F JL3.5 mm guiding
catheter and via a guidewire through a sheath placed via cut-down of the external
carotid artery and under direct angiographic guidance. One to two low pressure
inﬂations were performed to deploy the ICDD as close as possible to the site of
ameroid placement. All animals were pretreated for 48 h with aspirin (4 mg/kg),
clopidigrel (0.9 mg/kg) and verapamil (1.5 mg/kg). Aspirin and clopidigrel were
continued until sacriﬁce date. Prior to sacriﬁce (4 weeks after stent placement),
repeat angiography was performed to evaluate collateral formation. Hemody-
namic and electrocardiographic monitoring was performed for all invasive pro-
cedures. Animal sacriﬁce was performed under anesthesia utilizing an intravenous
sodium pentobarbital injection.2.4. Tissue processing, histological and immunoﬂuorescent staining analyses
For all analyses, operators were blinded as to the group fromwhich the samples
originated. At sacriﬁce, the heart was immediately harvested and samples were
obtained. Sections of myocardial areas of interest supplied by the left circumﬂex
artery were obtained adjacent to ameroid placement and were directly placed in
OCT medium (CellPath). The ICDD was removed by dissection of a small section of
myocardium immediately overlying the vessel wall and plastic embedded for
sectioning as described previously [13]. The ameroid constrictor was visualized to
verify the degree of occlusion. The remaining myocardium including the region
supplied by the CTO/ICDD was placed in 4% formalin for ﬁxation. Microvessels were
identiﬁed and quantiﬁed using immunoﬂuorescent staining of a-SMA (clone 1A4,
Dako) and CD31 (rabbit polyclonal, Abcam) followed by imaging using confocal
microscopy (Nikon eC1 plus, TE2000E).2.5. Endothelial colony identiﬁcation
At baseline, prior to ameroid placement, at time of ICDD deployment and prior
to sacriﬁce, 50 ml samples of whole blood were obtained for analysis. Using a Ficoll
density gradient, the mononuclear cell layer was obtained and was cultured on a
ﬁbronectin coated 12 well plates with endothelial differentiation medium EGM-2 as
previously described [14]. Culture media was changed at 3, 6 and 9 days at which
time colony counting was performed. Endothelial cell colonies were initially iden-
tiﬁed morphologically using light microscopy and veriﬁcation was made using
endothelial marker staining.2.6. Micro-CT imaging and analysis
Coronary arteries implanted with ICDD-Control or ICDD-VEGF were prepared
and scanned using micro-CT as previously described [15]. Brieﬂy arteries were
scanned in 2 cm contiguous segments along the length of the vessel 2 cm either side
of the implanted region and within the device segment along the luminal axis. The
micro-CT scanner was conﬁgured so that the cubic voxel dimension was 20 mm (16
bit gray scale). Three dimensional images were displayed using image analysis
software (Analyze 4.0, Biomedical Imaging resource, Mayo Clinic, Rochester, MN). In
each cross section vasa vasorumwere manually identiﬁed and vasa vasorum spatial
density (number of vasa vasorum/mm2 vessel wall area) assessed across each
stented segment. The mean value for multiple slices per 2 cm coronary segment was
derived for each animal.2.7. Microsphere injection and processing
Colored ﬂuorescent microspheres were injected into the left ventricle through
a pigtail catheter at 4 weeks following ameroid placement and 4 weeks following
stent implantation. Injections of 5.0  106 microspheres were performed during a
resting conditions as well as adenosine administration (400 mg/kg/min)-mediated
maximal vasodilatation [16] as described previously [17]. Withdrawal of reference
samples was performed through a 7F guiding catheter placed in the descending
thoracic aorta through a sheath placed via a femoral artery cut-down procedure at
a rate of 8 ml/min using a Harvard pump. After formalin ﬁxation, the myocardium
was divided into 3 short axis sections (apex, mid, base). These sections were then
further divided into circumferential wedge sections of epicardial and endocardial
tissue (<3 g). This tissue was weighed and sent for automated ﬂuorescence
counting (Interactive Medical Technologies, Irvine CA). RBF measurements were
made using the formula: RBF (ml/min/gram) ¼ (total tissue microspheres)/(tissue
weight,g)*(reference spheres/ml/min). The change in RBF between and, DRBF was
calculated by subtracting the RBF at stenting from the RBF value at sacriﬁce for
each sample.
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Tube formation for in vitro angiogenesis analysis was performed as previously
described [18]. Brieﬂy, a 96-well plate was coated with 50 ml of Matrigel (Becton
Dickinson Labware, Bedford, MA), which was allowed to solidify at 37 C for 1 h.
Human endothelial cells (1.5  104 cells per well) labeled with CellTracker Green
(Molecular Probes) were treated with conditioned media from control or VEGF-
secreting SMC, co-seeded with smooth muscle cells (1.5  103 cells per well)
labeled with CellTracker Orange on the Matrigel and cultured in M199 conditioned
medium, respectively. The cells were incubated for 20 h, and complete tubes from
randomly chosen ﬁelds were captured using Nikon EZC1-3.30 software on a
confocal microscope system (Nikon eC1 plus, TE2000E). Tube length, network area
and SMC-EC coverage analysis were performed using ImageJ software (NIH,
Bethesda, MD).2.9. Sixty-four-slice CT imaging, image reconstruction and data analysis
Cardiac CT imaging was performed using a 64-slice scanner (GE Discovery VCT
RX) with Iodixanol (Visipaque 320; Amersham Health) contrast agent. All gated CT
images were reconstructed at a 1.25 mm slice thickness, and phase data on all
axial slices were reconstructed from 0% to 99% of the cardiac cycle in 9% in-
crements for assessment of LV function parameters and ejection fraction (EF), as
calculated on an online workstation (AW 4.4; GE Healthcare). Sixty-four-slice
images were analyzed with CardIQ software (AW 4.4) to generate polar maps of
regional wall motion and quantiﬁed as mm2/g myocardial mass/cardiac cycle.
Myocardial perfusion was evaluated by contrast intensity 5 s after bolus injection
as described previously [17]. Relative Hounsﬁeld Unit (HU) measurement was
calculated as the mean HU in the LCx-related region compared to mean HU in the
LV chamber and normalized to the initial scan at the time of ameroid constrictor
placement.2.10. Statistical analyses
For in vivo experiments, signiﬁcance was calculated using the Kruskal Wallis
test followed by Dunn's Multiple Comparison test. For in vitro analyses, compar-
isons between treatment groups were made using ANOVA and Mann Whitney
tests.3. Results
3.1. ICDD-VEGF and local angiogenic indices in vivo
Seeding densities of approximately 1  107 SMC per cm2 of
ICDD were achieved in vitro over a 7 day period (Fig. 2(A) and
Supplementary Fig. I). Immunoﬂuorescence analyses display the
expected staining pattern for the VEGF165 isoform which is both
secreted from the Golgi apparatus and identiﬁed as bound in
extracellular matrix [19] in a punctuate granular localization
pattern (Fig. 2(A)). VEGF secretion from the cell mass within the
ICDD was conﬁrmed by ELISA to be in the nanogram/ml range
(Fig. 2(B)). There was no observable difference in growth
rate between untransduced and VEGF-producing SMCs. To
examine in vivo cell retention, autologous SMC were seeded into
an ICDD and implanted into normal porcine coronary arteries.
Retention of the cell mass was conﬁrmed using green ﬂuores-
cent protein (GFP) tracking, within the recipient vessel at 4
weeks after implantation with no evidence of implanted cell
migration outside of mesh or into the perivascular space
(Fig. 2(C)). Local angiogenic potential of ICDD-VEGF was
evaluated using micro-CT (Fig. 2(D)) and compared to untrans-
duced SMC within ICDD-Control groups [20]. ICDD-VEGF
induced a > 2 fold augmentation in vasa vasorum density
within an arborized vascular network extending across internal
and external vasa vasorum (p < 0.01, Fig. 2(E)). Secreted VEGF
in the region of the ICDD-VEGF was quantiﬁed by ELISA analysis
of tissue within and outside of the ICDD-VEGF recipient
coronary artery segments. Local VEGF concentrations were
increased >10 fold within the recipient vessel segments
compared to the surrounding region or ICDD-Control treated
animals (Fig. 2(F)). These data underscore marked accumulation
of VEGF within a restricted region of the ICDD-VEGF recipientartery and a gradient of VEGF to the surrounding tissue. As high
local VEGF concentrations have previously been intimately
linked to endothelial progenitor cell (EPC, Supplementary Fig. II)
mobilization [21], we tested, by endothelial cell colony forming
unit (EC:CFU) assay (Fig. 2(G)), vasculogenic potential of pe-
ripheral blood mononuclear cells obtained from ICDD-VEGF and
ICDD-Control-treated animals. a > 5 fold increase in EC:CFU in
culture was observed in ICDD-VEGF animals compared to con-
trols (Fig. 2(H)).3.2. ICDD-VEGF placement and regional MBF
Myocardial perfusion, evaluated by contrast multi-detector
computed tomography (MDeCT) [17], conﬁrmed enhanced
perfusion in ventricular wall supplied by ischemic LCx in ICDD-
VEGF but not in ICDD-Control (Fig. 3(A and B)). Moreover, real
time angio-ﬂuoroscopy indicated, in some animals with ICDD-
VEGF, the presence of bridge collateral formation across the
occlusive segment with anterograde perfusion of the distal artery
(Supplementary video). Regional MBF was evaluated using gold
standard colored microsphere analysis. Previous studies have
evaluated perfusion in healthy porcine myocardium as between
0.8 and 1.0 ml/min/gramme of tissue [22]. Our baseline data was
consistent with these values (Supplementary Fig. VI). At baseline,
under resting conditions, treated animals with ICDD-VEGF had a
~20 fold increase in MBF within the occlusive and border zones of
the ischemic myocardium (Fig. 3(C)). This increased blood ﬂow
was observed in both the endocardial and epicardial ischemic
compartments across the full length of the left ventricular
chamber (base, midzone, apex). Animals with ICDD-VEGF
exhibited a 3e5 fold increase in MBF during adenosine stress in
both the occlusive and border zones respectively compared to
controls. These increased stress perfusion effects were evident
across all ischemic myocardial segments from ventricular base to
apex (Fig. 4).
Supplementary video related to this article can be found at
http://dx.doi.org/10.1016/j.biomaterials.2014.07.016.3.3. VEGF-secreting cells and angiogenesis
Analysis of angiogenesis in the myocardium distal to the site of
occlusion by immunoﬂuoresence revealed increased numbers of a-
smooth muscle actin and CD31 dual positive arterioles (Fig. 5(A)) in
ICDD-VEGF when compared to ICDD-Control animals (p < 0.001,
Fig. 5(B)). To examine the arteriogenic capacity of VEGF-producing
SMC in a deﬁned system, conditioned media driven EC and EC/SMC
tube formation in matrigel were performed. Conditioned media
fromVEGF-secreting but not control SMC signiﬁcantly enhanced EC
tube network formation in terms of network area (p < 0.05, Fig. 5(C
and D)) and perivascular SMC integration into these EC networks
(p < 0.05, Fig. 5(E and F)).3.4. ICDD-VEGF and LV function following CTO
Whether the improvements elicited by ICDD-VEGF placement
in regional blood ﬂow translated to improvements in hemody-
namic function was evaluated since the extent of myocardial
injury and LV function may be correlated with the degree of
therapeutic arteriogenesis in patients with CTO [23]. Global and
regional LV function and hemodynamics were assessed four
weeks after ICDD placement using cardiac CT and conductance
catheter measurements. ICDD-VEGF signiﬁcantly improved
global LV ejection fraction by CT (Fig. 6(A)), dp/dt by PV loop
Fig. 2. VEGF-secreting cell mass within ICDD increased angiogenesis and angiogenic indices in vivo. A. Immunoﬂuorescence analysis of VEGF (green) expression in vitro in
SMC within ICDD-VEGF with DAPI-stained nuclei (blue) showing a granular localization pattern characteristic of secreted proteins (Scale bar: 50 mm, n ¼ 3). B. Quantiﬁcation
of VEGF secretion from control or VEGF engineered SMCs by ELISA (*:p < 0.01 versus control, n ¼ 10). C. Transverse section of pig circumﬂex artery showing stably
implanted ICDD with SMC expressing GFP 1 month following implantation (Scale bar: 200 mm). D,E. Micro-CT analysis showing increased vasa vasorum density across ICDD
recipient segments compared to ICDD-Control treatment of normal coronary arteries (scale bar: 5 mm, *:p < 0.05, n  5 for each group). F. ELISA analysis of ICDD
recipient artery and underlying intima (I) or tissue taken from outside the ICDD treated vessel (O) showing increased intimal VEGF levels associated with ICDD-VEGF
placement (ﬁlled bars) versus control ICDD (open bars) (*:p < 0.05, n  5 for each group). G. Endothelial cell colony forming units (EC:CFU) from the peripheral
blood labeled with acetylated LDL (scale bar: 500 mm). H. Enhanced EC:CFU in the peripheral blood of pigs treated with ICDD-VEGF versus control. (*:p < 0.05, n  5 for each
group).
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and D)) demonstrating signiﬁcant functional recovery that was
concomitant with increased perfusion in the ischemic zone, as
well as histologic and immunohistochemical evidence of
arteriogenesis.4. Discussion
Despite decades of advances in pharmacologic, device and
surgical treatment of occlusive vascular disease, a cohort of
symptomatic, non-revascularizable atherosclerotic patients remain
Fig. 3. ICDD-VEGF delivery increased contrast perfusion and regional blood ﬂow at rest in a porcine CTO model. A. Contrast perfusion in ICDD-VEGF and ICDD-Control animals
in territory supplied by occluded LCx artery outlined in red at the time of ICDD placement and four weeks later. CT artefact from ameroid constrictor is highlighted (blue). B.
Quantiﬁcation of CT contrast perfusion in ICDD-VEGF compared with ICDD-Control expressed as change in Hounsﬁeld units DH.U.) between deployment and 4 weeks (*:p < 0.05). C.
Relative changes in MBF following ICDD-Control or ICDD-VEGF placement at rest measured quantitatively by colored microsphere analysis (*: p < 0.0001, ¶: p < 0.001 z: p < 0.01;
Kruskal Wallis test, n  6 per each group). Keys to tissue sampling and color coding representing change in relative blood ﬂow DRBF, ml/min/g tissue) between time of ICDD
placement and sacriﬁce is displayed.
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Fig. 4. ICDD-VEGF increased regional blood ﬂow during adenosine cardiac stress in porcine CTO model. Relative changes in MBF four weeks following ICDD-Control or ICDD-
VEGF placement during adenosine-induced stress measured quantitatively by colored microsphere analysis (*: p < 0.0001, ¶: p < 0.001 z: p < 0.01; Kruskal Wallis test, n ¼ 10). Keys
to tissue sampling and color coding representing change in relative blood ﬂow DRBF, ml/min/g tissue) between time of stent placement and sacriﬁce is displayed.
A.H.S. Kumar et al. / Biomaterials 35 (2014) 9012e90229018[24]. These patients with chronic vascular occlusion are frequently
unsuitable for percutaneous coronary intervention (PCI) due to
procedural risk and high restenosis rates, and may not be ideal
candidates for surgical revascularization due to poor distal vessel
targets, unfavorable co-morbidities or lack of suitable bypass
conduits [5]. Gene and more recently cell therapy have been
touted as a therapeutic answer for these no-option patients [25]
but these approaches still lack sufﬁcient site speciﬁc targeting,
and are hampered by dissipation of therapeutic effect through
dilution and dispersion of gene/cell product within the wider
vascular system [26].
The aim of this study was to synergize cell and gene therapy
beneﬁts using a tissue engineered ICDD to enhance site speciﬁc
angiogenesis in a model of chronic myocardial ischemia. We
posited that an ICDD secreting VEGF transgene product could be
delivered safely to a site of chronic vascular occlusion and would
promote increased myocardial blood ﬂow and improved cardiac
function in the ischemic zone of a porcine ameroid constrictor CTOmodel. In the current study, we demonstrate that ICDD-VEGF
promotes signiﬁcant increases in regional ischemic zone MBF by
gold standard color microsphere detection, regional cardiac func-
tion by CT contrast imaging and regional arteriogenesis by immu-
nohistochemical microvessel analysis. Moreover, we show that
increased blood ﬂow is likely driven by both vasculogenic and
arteriogenic processes incorporating endothelial and SMC-pericyte
investment of nascent microvessels. Finally, the functional conse-
quences of this augmented angiogenesis includes a > 50 fold in-
crease in ischemic zone MBF in VEGF compared to control-
treatment under both rest and adenosine-induced stress condi-
tions, with attendant improvement in regional wall motion and
global LV functional parameters.
VEGF has been widely used in the past for stand-alone gene
therapy but limitations were observed in terms of plasmid vector
dispersion and lack of site speciﬁcity when delivered via the
intravascular delivery route, ineffective therapeutic dosing and
lack of transgene persistence in the case of adenoviral vectors
Fig. 5. ICDD-VEGF enhanced angiogenesis in vivo, and SMC-VEGF secretome augmented in vitro EC tube formation and perivascular SMC association with EC network on
matrigel. A. Immunoﬂuorescent analyses of CD31 (green) and a-SMAþ (red) microvessels in myocardial territory supplied by LCx (scale bar: 100 mm). B. Quantiﬁcation of
microvessel formation showing an increase in a-SMA positive microvessels with ICDD-VEGF placement (*: p < 0.05). C,D Conditioned media from VEGF-secreting SMC signiﬁcantly
enhanced in vitro angiogenic activity of EC cultured in matrigel with regard to sprout length and overall network area (scale bar: 300 mm*: p < 0.05). E. Conditioned media from
VEGF-secreting SMC also increased SMC association with EC tubular networks on matrigel compared to control SMC conditioned media. Note red SMC attached to EC tubes (green
tubular network). F. Quantiﬁcation of data represented in E (n  6 per each group, scale bar: 200 mm, *: p < 0.05). (For interpretation of the references to colour in this ﬁgure legend,
the reader is referred to the web version of this article.)
A.H.S. Kumar et al. / Biomaterials 35 (2014) 9012e9022 9019[26]. ICDD-VEGF gene therapy using autologous SMC stably
expressing transgene aimed to address these vector and delivery
limitations providing a stable in vivo platform for engineered
cells that was site speciﬁc. The ICDD design allowed precise
ex vivo calculation of VEGF secretion patterns and dose prior to
implantation and facilitated complete protection of cells from
barotrauma of balloon deployment and dispersion when
compared to more conventional gene delivery strategies [27].
This ICDD approach thus provides a more persistent and stable
supply of VEGF locally in addition to the beneﬁt of comple-
mentary paracrine factors released from engineered SMC within
the device.
Autologous SMCs were selected for high dose stable VEGF
gene transfer as well as an ability to facilitate local arteriogenesis
not evident in previous single VEGF gene therapy studies [28]. As
a substrate for scaffold for cell delivery, the topography of a non-
woven and pressed mesh offers many advantages over non-
pressed materials including cell coverage, retention and ECM
production [29] since the close proximity of the ﬁbers allows
cells to proliferate and migrate in a three-dimensional space. The
non-woven scaffold geometry was used in combination with
ﬁbronectin coating which favors a synthetic phenotype ininitially seeded SMC [30] which in turn would enhance cell
loading, proliferation within the mesh. We were therefore able to
achieve both sustained implanted cell retention and local VEGF
production following ICDD placement. SMC were reverted to
contractile phenotype with 48 h heparin treatment prior to im-
plantation [31]. We conﬁrmed that conditioned media from VEGF
engineered SMC augmented endothelial tube formation and
smooth muscle cell pericyte-like association with endothelial
tubes on matrigel in vitro compared conditioned media from
non-engineered SMC (Fig. 5). This supports a complementary
paracrine secretome of VEGF engineered SMC that may
contribute to additional vasculogenic and arteriogenic compo-
nents of angiogenesis in our model. Indeed, we show multiple
aspects of this angiogenic biology is enhanced by in vivo ICDD-
VEGF treatment including mobilization of cells with endothelial
colony forming potential and a-smooth muscle actin associated
microvessel formation (arterioles 100 mm in diameter) in the
territory supplied by the device. Local VEGF delivery has previ-
ously been shown to mobilize and improve survival of circulating
[32] and vessel wall [33] derived progenitor cells so it is
conceivable that both these effects contributed to angiogenesis in
our study. Blood ﬂow to the ICDD-VEGF treated area may allow
Fig. 6. ICDD-VEGF enhanced global LV ventricular function, hemodynamics and
regional wall motion in porcine CTO model. A. Assessment of LV ejection fraction
by contrast CT at time of ICDD placement (4 wks) and 1 month later (8 wks) and B.
dp/dt by PV loop analysis both showed improvement with ICDD-VEGF compared to
ICDD-Control treatment at 8 wks. C. Quantiﬁcation of the improvement in regional
wall motion elicited by ICDD-VEGF delivery compared to ICDD-Control treatment
(n  6 per each group, *:p < 0.05). Initial histogram data in panels A and B relate
to baseline CT parameters in pigs before creation of vascular occlusions with
ameroid.
A.H.S. Kumar et al. / Biomaterials 35 (2014) 9012e90229020circulating cells known to express VEGF receptors including
monocytes, and blood-derived progenitor cells, contact with a
low level continual source of VEGF. Circulating monocytic cells,
whose subpopulations include putative endothelial cell colony
forming cells, augmented in our study, may also functionally
contribute to this angiogenesis, as previously demonstrated by
others in models of peripheral ischemia [34].
We further hypothesize that local production of VEGF creates
a concentration gradient which promotes capillary sprouts and
that additional secretion of other growth factors by resident
smooth muscle cells and perhaps other cells in the local area of
the stent contributes to both angiogenesis and arteriogeneisis in
the ischemic myocardial region supplied by the ICDD. Secretion
of complementary growth factors by resident and VEGF-engineered SMC may also have contributed to arteriogeneisis in
the ischemic myocardial region supplied by the ICDD. It is
conceivable that this arteriogenic network connects with the
microvasculature within the ischemic region beyond the initial
site of delivery and that additional secretion of complementary
growth factors such as PDGF by engineered SMC [10] may have
augmented arteriogenesis in the ICDD-VEGF setting. This is borne
out by the marked increases in downstream blood ﬂow observed
in our microsphere analysis experiments. Previous evidence from
murine intramuscular gene therapy models indicates that
elevated VEGF concentrations in a local microenvironment as
opposed to a total systemic dose is a key determinant of
angiogenesis following vector delivery [35]. Indeed, a “spatial
delivery-efﬁcacy mismatch” has been identiﬁed in the case of
intramyocardial injections of VEGF in which an improvement of
MBF is observed at sites adjacent to, in addition to those directly
targeted by injections [36]. In our own study this concept is
supported by the marked increases in downstream blood ﬂow
observed in our microsphere analysis experiments. Such local
VEGF concentration gradients contributing to arteriogenesis have
also been demonstrated by others in non-cardiac environments
[37].
Formation of capillary networks instead of larger conductance
microvessels has been identiﬁed as one of the shortcomings of
earlier therapeutic angiogenesis strategies. Accepting Pois-
seuille's law on ﬂow relating to the fourth potency of diameter,
in order to replace a conductance artery, a large number of
capillaries would need to be created. Although we did not
speciﬁcally test for vessel leakage with dye methodology, the
microvessels we observed histologically were of good
morphology with both SMC and endothelial cell elements. Our
data indicate that new, and stable microvascular networks,
formed post ICDD-VEGF treatment, were capable of appropriate
exercise load and regional functional augmentation responses
approaching those previously achieved by macrovascular bypass
[38]. More importantly, we show here that augmented micro-
vascular angiogenesis present in the ICDD-VEGF group can
improve global LV function an effect that may have implications
for chronic ischemic cardiomyopathy treatment. For instance, a
large proportion of cell therapy studies are currently targeted at
this speciﬁc patient cohort.
Given that the backbone of the ICDD involves a conventional
stent design which aids percutaneous delivery we anticipated
that SMC seeded within the stent would cause some neointimal
response as predicted from previous work [9]. However since our
therapeutic angiogenesis strategy involved acceptance of a pre-
existing CTO lesion that in this model, would not be macro-
luminally revascularized or stented we believed that some in-
device restenosis would be acceptable during the proof of
concept phase of development. It is possible that future itera-
tions of this ICDD platform could incorporate additional elements
that might include biodegradability, on-off transgene regulation
and restenosis mitigation strategies. Importantly our data
conﬁrm that, although some restenosis was observed especially
on the distal end of the ICDD (Supplementary Fig. IV), this did
not prospectively impair the robust angiogenic capacity of the
implanted device. Indeed we know of no other large animal gene
therapy study with a similar augmentation in blood ﬂow be-
tween control rest-ischemic and ICDD-VEGF stress-ischemic
states.
5. Conclusions
This cell-based, percutaneously delivered, gene therapy system
presented as a proof of concept study can provide a sustained
A.H.S. Kumar et al. / Biomaterials 35 (2014) 9012e9022 9021therapeutic transgene product that signiﬁcantly improves blood
ﬂow to ischemic myocardium, translating into regional and global
left ventricular functional recovery. This system may have impli-
cations for non-revascularizable no-option patients or may be
adapted to other vascular beds such as in the peripheral
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